Nucleai, an Israeli medtech startup that uses artificial intelligence (AI) powered spatial biology to transform drug development and clinical treatment decisions for precision cancer treatments, raised $33 million in a Series B financing round, jointly led by Section 32 and Sanofi Ventures.
Spatial Biology is the study of tissues within their own 2D or 3D context. Think of how a GPS system captures location coordinates within an area and tracks your location at a given time – the same principle can be used on a cellular and molecular level for the treatment of disease.
And Nucleai is certainly not alone when it comes to Israeli medtech startups. Earlier this month MDClone, an Israeli medtech startup and digital health company, raised $63 million to provide clinicians and healthcare professionals with the ability to explore healthcare data independently and without barriers. As for medtech that is used specifically for cancer treatment, Nucleix, an Israeli startup that offers a liquid biopsy which it says can detect cancer early, secured an additional $22 million in funding in January, as an extension to the previously announced $55 million financing, bringing the total capital that the company raised in 2021 to $77 million.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Established in 2018, Nucleai is an AI-powered spatial biology company who declares its mission to be to transform drug development and clinical treatment decisions by unlocking the power of pathology data. Nucleai provides pharmaceutical companies, contract research organizations, and diagnostics laboratories with a state-of-the-art AI platform to improve clinical trials and clinical decision-making.
“Nucleai’s vision is to bring spatial biology to the forefront of precision medicine and to embed the use of our platform in every clinical trial involving tissue over the next few years,” said Avi Veidman, CEO of Nucleai. “We are pleased to bring world-class investors who share our passion and vision to transform drug development and clinical treatment decisions by combining artificial intelligence, big data, spatial biology, and a comprehensive software platform.”